

Supplementary Information for

Palladium-Catalyzed Double C-H Activation: One-Pot Synthesis of Benzo[c]pyrazolo[1,2-a]cinnolin-1-ones from 5-Pyrazolones and Aryl Iodides

*Zhoulong Fan,^a Kui Wu,^b Li Xing,^c Qizheng Yao^b and Ao Zhang^{*a}*

^a CAS Key Laboratory of Receptor Research, and Synthetic Organic & Medicinal Chemistry Laboratory (SOMCL), Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China. E-mail: aozhang@simm.ac.cn

^b Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China

^c Nano Science and Technology Institute, University of Science and Technology of China, Suzhou 215123, China


Table of Contents







1. General Experimental Information.....	S2
2. Optimization Results of the Reaction Conditions.....	S2
3. General Procedure and the results for Synthesis of Mono-arylation Products 4	S5
4. General Procedure for One-pot Synthesis of Benzo[c]pyrazolo [1,2-a]cinnolines 1	S6
5. Determination of Tautomers 3a and 3a' in TFA by ¹ H NMR	S7
6. Additional Experiments for Mechanism Study.....	S7
7. Spectroscopic Data of All New Compounds.....	S8
8. References.....	S18
9. Copies of NMR Spectra Data.....	S19
10. X-ray Data of Compound 1n	S61








1. General Experimental Information: All reactions were performed in glassware containing a Tefloncoated stir bar. All solvents and chemical reagents were obtained from commercial sources and used without further purifications. ^1H and ^{13}C NMR spectra were recorded with tetramethylsilane as an internal reference. Low and high-resolution mass spectra were obtained in the EI mode. Flash column chromatography on silica gel (200-300 mesh) was used for the routine purification of reaction products. The column output was monitored by TLC on silica gel (100-200 mesh) precoated on glass plates (15 x 50 mm), and spots were visualized by UV light at 254 or 365 nm.

2. Optimization Results of the Reaction Conditions:

Table 1 Arylation of edaravone (**3a**) under different conditions.^a




Entry	Substrate	Cat.	Solvent	Temp.	Time	Yield, % ^b
1	 (1.5eq)	Pd(OAc) ₂ (0.1eq)	CF ₃ COOH(0.2M)	100°C	23h	72%
2	 (2eq)	Pd(OAc) ₂ (0.1eq)	CF ₃ COOH(0.2M)	100°C	17h	75%
3	 (3eq)	Pd(OAc) ₂ (0.1eq)	CF ₃ COOH(0.2M)	100°C	8h	74%
4	 (4eq)	Pd(OAc) ₂ (0.1eq)	CF ₃ COOH(0.2M)	100°C	4h	75%
5	 (5eq)	Pd(OAc) ₂ (0.1eq)	CF ₃ COOH(0.2M)	100°C	2.5h	75%
6	 (5eq)	PdCl ₂ (0.1eq)	CF ₃ COOH(0.2M)	100°C	3h	52%

7	 (5eq)	$\text{Pd}(\text{TFA})_2$ (0.1eq)	CF_3COOH (0.2M)	100°C	3h	49%
8	 (5eq)	$\text{Pd}_2(\text{dba})_3$ (0.1eq)	CF_3COOH (0.2M)	100°C	4h	11%
9	 (5eq)	$\text{Cu}(\text{OAc})_2$ (0.1eq)	CF_3COOH (0.2M)	100°C	-	0
10	 (5eq)	$\text{Pd}(\text{OAc})_2$ (0.1eq)	CH_3COOH (0.2M)	100°C	3h	0
11	 (5eq)	$\text{Pd}(\text{OAc})_2$ (0.1eq)	$\text{CF}_3\text{COOH}/$ $\text{CH}_3\text{COOH}(1/1,0.2\text{M})$	100°C	4h	24%
12	 (5eq)	$\text{Pd}(\text{OAc})_2$ (0.1eq)	CF_3COOH (0.2M)	80°C	3h	<5%
13	 (5eq)	$\text{Pd}(\text{OAc})_2$(0.1eq)	CF_3COOH(0.2M)	120°C	1.5h	82%

^a Unless stated otherwise, all reactions were carried out using edaravone **3a** (50 mg, 0.287 mmol), aryl iodide **5a** (1.5-5 equiv), Cat. (10 mol %), AgOAc (1.5 equiv), and Solvent (0.2 M) at 80-120 °C for 1.5-23 h. ^b Isolated yields.


Table 3 Cyclization of **4aa** under different conditions.^a



Entry	Cat.	Base	Oxidant	Solvent	Time	Yield, % ^b
1	Pd(OAc) ₂	-	AgOAc	TFA (0.2 M)	24h	5%
2	Pd(OAc) ₂	-	-	TFA (0.2 M)	24h	9%
3	Pd(OAc) ₂	-	-	TFA (0.2 M)	24h	0
4	-	-	AgOAc	TFA (0.2 M)	24h	0
5	-	-	-	TFA (0.2 M)	24h	0
6	Pd(OAc) ₂	K ₂ CO ₃		TFA (0.2 M)	12h	17%
7	Pd(OAc) ₂	Cs ₂ CO ₃		TFA (0.2 M)	12h	12%
8	Pd(OAc) ₂	CsF		TFA (0.2 M)	12h	8%
9	Pd(OAc) ₂	NaH ₂ PO ₄ ·2H ₂ O		TFA (0.2 M)	12h	6%
10	Pd(OAc) ₂	K ₂ CO ₃	AgOAc	TFA (0.2 M)	12h	25%
11	Pd(OAc) ₂	K ₂ CO ₃	Ag ₂ O	TFA (0.2 M)	12h	20%
12	Pd(OAc)₂	K₂CO₃	K₂S₂O₈	TFA (0.2 M)	12h	54%
13	Pd(OAc) ₂	K ₂ CO ₃	Cu(OAc) ₂	TFA (0.2 M)	12h	trace
14	Pd(OAc) ₂	K ₂ CO ₃	(NH ₄) ₂ S ₂ O ₈	TFA (0.2 M)	12h	40%
15	Pd(OAc) ₂	-	K ₂ S ₂ O ₈	TFA (0.2 M)	12h	47%
16	Pd(OAc) ₂	K ₂ CO ₃	K ₂ S ₂ O ₈	TFA (0.1M)	24h	55%
17 ^c	Pd(OAc)₂	K₂CO₃	K₂S₂O₈	TFA (0.1 M)	24h	74%
18	Pd(OAc) ₂	K ₂ CO ₃	K ₂ S ₂ O ₈	TFA (0.05 M)	24h	60%
19	Pd(OAc) ₂	K ₂ CO ₃	K ₂ S ₂ O ₈	TFA (0.03 M)	24h	70%
20	Pd(OAc) ₂	K ₂ CO ₃	K ₂ S ₂ O ₈	TFA (0.02 M)	24h	78%
21 ^{c,d}	One-pot from 3a + 5a			TFA (0.1 M)	15h	76%
22 ^{c,d}	One-pot from 3a + 5a (no Base)			TFA (0.1 M)	15h	66%

^a Unless stated otherwise, all reactions were carried out using 5-pyrazolone **4aa** (0.2 mmol), Pd(OAc)₂ (0.02 mmol) in reflux TFA at 120 °C, the reaction time (12 - 24 h) was determined by TLC analysis. ^b Isolated yields. ^c Reaction run in TFA (0.1 M) in a sealed tube. ^d Experiment procedure following the synthesis of **1**.

3. General Procedure for Synthesis of Mono-arylation Products **4**:



(**3**)^{1,2} (0.5 mmol), AgOAc (125 mg, 0.75 mmol) and Pd(OAc)₂ (11 mg, 0.05 mmol) in TFA (2.5 mL) was added aryl iodides (**5**) (2.5 mmol), the mixture was heated to 120 °C and monitored by TLC. After the starting material completely disappeared, the reaction mixture was filtered and the filtrate was concentrated. The residue was purified on a silica gel column with petroleum ether/ethyl acetate (2/1) to give the corresponding products **4** (Table 2).


Table 2 Results of the reaction of 5-pyrazolones **3** with aryl iodides.^a

Entry	3a-g (R=)	5a-l (R'=)	Time	Yield ^b
1	3a (H)	5a (H)	1.5 h	4aa , 82%
2 ^c	3a (H)	5b (4'-Me)	2.5 h	4ab , 83%
3 ^c	3a (H)	5c (4'-F)	12 h	4ac , 87%
4 ^c	3a (H)	5d (4'-Br)	13 h	4ad , 82%
5 ^c	3a (H)	5e (4'-Bu ^h)	4.5 h	4ae , 71%
6	3a (H)	5f (4'-CO ₂ Me)	14 h	4af , 85%
7	3a (H)	5g (3'-OMe)	4.5 h	4ag , 70%
8	3a (H)	5h (3'-CO ₂ Me)	12 h	4ah , 86%
9 ^c	3a (H)	5i (3',5'-di-Me)	4 h	4ai , 68%
10	3a (H)	5j (3'-Cl)	10.5 h	4aj , 70%
11	3a (H)	5k (3'-F)	10 h	4ak , 90%
12	3a (H)	5l (3'-F-4'-Br)	24 h	4al , 76%
13	3b (4'-Me)	5a (H)	5 h	4ba , 91%
14	3c (4'-Cl)	5a (H)	5.5 h	4ca , 73%
15	3d (4'-NO ₂)	5a (H)	22 h	4da , 49%
16	3e (3'-Me)	5a (H)	6 h	4ea , 64%
17	3f (3'-F)	5a (H)	5.5 h	4fa , 75%
18 ^d	3g (3'-Cl-4'-Me)	5a (H)	20 h	4ga , 90%

^a Unless stated otherwise, all reactions were carried out using 5-pyrazolones **3** (0.5 mmol), aryl iodides **5** (2.5 mmol), Pd(OAc)₂ (0.05 mmol), AgOAc (0.75 mmol), and TFA (2.5 mL) at 120 °C for 1.5 - 24 h determined by TLC analysis. ^b Isolated yields. ^c Reaction run at 100 °C. ^d Sealed tube was employed.

4. General Procedure for One-pot Synthesis of Benzo[c]pyrazolo [1,2-a]cinnolines **1:** To a stirred solution of 5-pyrazolones (**3**) (0.5 mmol) in TFA (2.5 mL), AgOAc (125 mg, 0.75 mmol), Pd(OAc)₂ (11 mg, 0.05 mmol), and aryl iodides (**5**) (2.5 mmol) were added. The mixture was heated to 120 °C in a sealed tube till the starting material disappeared. After cooled to room temperature, Pd(OAc)₂ (11 mg, 0.05 mmol), K₂S₂O₈ (203 mg, 0.75 mmol), K₂CO₃ (138 mg, 1 mmol) and additional portion of TFA (2.5 mL) were added consecutively. The mixture was stirred at room temperature for 10 min under N₂ atmosphere, and then heated to 120 °C for 12-24 h in the sealed tube. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified on a silica gel column with petroleum ether/ethyl acetate (1/3) as the eluent to afford the corresponding products **1**.

5. Determination of Tautomers **3a and **3a'** in TFA by ¹H NMR:**




Compound 3a: ^1H NMR (300 MHz, CDCl_3) δ 7.86 (d, J = 8.2 Hz, 2H), 7.39 (t, J = 7.2 Hz, 2H), 7.18 (t, J = 7.4 Hz, 1H), 3.43 (s, 2H), 2.20 (s, 3H).

Compound 3a': ^1H NMR (300 MHz, CDCl_3 + 2 drops TFA) δ 13.36 (s, 2H), 7.40 (m, 5H), 5.71 (s, 1H), 2.25 (s, 3H).

6. Additional Experiments for Mechanism Study:

(1) Two Additional Experiments: Two additional substrates (4,4-dimethyl or *N*-methyl) were employed for the same Pd-catalyzed C-H activation/arylation and compound **7** was obtained in 72% yield, whereas *N*-methyl product **8** was not observed (Scheme 1).



Scheme 1 Palladium-catalyzed C-H activation reaction of 1-phenyl 5-pyrazolones derivatives.

(2) Synthesis of 1-([1,1'-Biphenyl]-2-yl)-3,4,4-trimethyl-1H-pyrazol-5(4H)-one (7): To a stirred solution of 3,4,4-trimethyl-1-phenyl-1H-pyrazol-5(4H)-one³ (20 mg, 0.1 mmol), AgOAc (25 mg, 0.15 mmol) and Pd(OAc)₂ (2 mg, 0.01 mmol) in TFA (1 mL), was added phenyl iodide (**5a**) (56 μL , 0.5 mmol). The mixture was heated to 120 °C and monitored by TLC. After completion, the mixture was filtered and the filtrate was evaporated to dryness in vacuo. The residue was separated on a silica gel column with petroleum ether/ethyl acetate (2/1) as the eluent to give product **7** (20 mg, 72% yield) as colorless oil.

7. Spectroscopic Data of All Products.

1-([1,1'-Biphenyl]-2-yl)-3-methyl-1H-pyrazol-5(4H)-one (4aa):⁴ White solid; mp = 101-103

°C; **¹H NMR** (400 MHz, CDCl₃) δ 7.47 – 7.39 (m, 4H), 7.37 – 7.27 (m, 5H), 3.13 (s, 2H), 2.04 (s, 3H); **¹³C NMR** (126 MHz, CDCl₃) δ 170.9, 155.4, 139.5, 138.9, 134.0, 130.4, 128.5, 128.0, 127.9, 127.8, 127.3, 126.8, 40.9, 16.5; **EI-MS** (m/z) 250 (M⁺); **HRMS** (EI): m/z [M⁺] calcd for C₁₆H₁₄N₂O, 250.1106; found, 250.1100.

3-Methyl-1-(4'-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrazol-5(4H)-one (4ab): Colourless oil; **¹H NMR** (400 MHz, CDCl₃) δ 7.43 – 7.38 (m, 4H), 7.22 (d, J = 8.1 Hz, 2H), 7.15 (d, J = 8.5 Hz, 2H), 3.11 (s, 2H), 2.35 (s, 3H), 2.04 (s, 3H); **¹³C NMR** (126 MHz, CDCl₃) δ 170.9, 155.5, 139.6, 136.4, 135.9, 133.9, 130.4, 128.5, 127.8, 127.7, 127.4, 40.9, 20.8, 16.5; **EI-MS** (m/z) 264 (M⁺); **HRMS** (EI): m/z [M⁺] calcd for C₁₇H₁₆N₂O, 264.1263; found, 264.1261.

1-(4'-Fluoro-[1,1'-biphenyl]-2-yl)-3-methyl-1H-pyrazol-5(4H)-one (4ac): White solid; mp = 163-165 °C; **¹H NMR** (400 MHz, CDCl₃) δ 7.43 (tt, J = 6.0, 3.3 Hz, 4H), 7.34 – 7.27 (m, 2H), 7.04 (t, J = 8.7 Hz, 2H), 3.16 (s, 2H), 2.07 (s, 3H); **¹³C NMR** (126 MHz, CDCl₃) δ 170.9, 162.7, 160.7, 155.6, 138.6, 134.9, 134.8, 134.0, 130.3, 129.7, 129.6, 128.6, 128.0, 127.3, 114.8, 114.6, 40.9, 16.5; **EI-MS** (m/z) 268 (M⁺); **HRMS** (EI): m/z [M⁺] calcd for C₁₆H₁₃FN₂O, 268.1012; found, 268.1009.

1-(4'-Bromo-[1,1'-biphenyl]-2-yl)-3-methyl-1H-pyrazol-5(4H)-one (4ad): White solid; mp = 142-144 °C; **¹H NMR** (400 MHz, CDCl₃) δ 7.48 (d, J = 8.4 Hz, 2H), 7.46 – 7.36 (m, 4H), 7.21 (d, J = 8.4 Hz, 2H), 3.16 (s, 2H), 2.07 (s, 3H); **¹³C NMR** (126 MHz, CDCl₃) δ 170.8, 155.7, 138.3, 137.9, 133.8, 130.9, 130.2, 129.6, 128.6, 128.3, 127.3, 121.1, 40.9, 16.6; **EI-MS** (m/z) 328 (M⁺); **HRMS** (EI): m/z [M⁺] calcd for C₁₆H₁₃BrN₂O, 328.0211; found, 328.0197.

1-(4'-(Tert-butyl)-[1,1'-biphenyl]-2-yl)-3-methyl-1H-pyrazol-5(4H)-one (4ae): Colourless oil; **¹H NMR** (400 MHz, CDCl₃) δ 7.48 – 7.42 (m, 4H), 7.39 (d, J = 8.3 Hz, 2H), 7.30 (s, 2H), 3.15 (s, 2H), 2.05 (s, 3H), 1.36 (s, 9H); **¹³C NMR** (126 MHz, CDCl₃) δ 171.1, 155.4, 149.6, 139.5, 135.8, 134.0, 130.5, 128.5, 127.6(2), 127.4, 124.7, 40.9, 34.1, 30.9, 16.4; **EI-MS** (m/z) 306 (M⁺); **HRMS** (EI): m/z [M⁺] calcd for C₂₀H₂₂N₂O, 306.1732; found, 306.1732.

Methyl 2'-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-[1,1'-biphenyl]-4-carboxylate (4af): Colourless oil; **¹H NMR** (400 MHz, CDCl₃) δ 8.06 – 8.00 (m, 2H), 7.48 – 7.39 (m, 6H), 3.92 (s, 3H), 3.15 (s, 2H), 2.05 (s, 3H); **¹³C NMR** (126 MHz, CDCl₃) δ 170.8, 166.5, 155.9, 143.7, 138.1, 133.9, 130.2, 129.1, 128.9, 128.5, 128.4, 128.0, 127.2, 51.7, 40.9, 16.5; **EI-MS** (m/z) 308 (M⁺); **HRMS** (EI): m/z [M⁺] calcd for C₁₈H₁₆N₂O₃, 308.1161; found, 308.1155.

1-(3'-Methoxy-[1,1'-biphenyl]-2-yl)-3-methyl-1H-pyrazol-5(4H)-one (4ag): Colourless oil; ^1H NMR (400 MHz, CDCl_3) δ 7.48 – 7.42 (m, 4H), 7.28 (d, J = 3.0 Hz, 1H), 6.97 – 6.91 (m, 2H), 6.90 – 6.83 (m, 1H), 3.80 (s, 3H), 3.15 (s, 2H), 2.07 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 171.1, 158.9, 155.5, 140.2, 139.5, 133.9, 130.4, 128.8, 128.6, 128.0, 127.5, 120.4, 113.2, 112.8, 54.7, 40.9, 16.5; **EI-MS** (m/z) 280 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{17}\text{H}_{16}\text{N}_2\text{O}_2$, 280.1212; found, 280.1209.

Methyl 2'-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-[1,1'-biphenyl]-3-carboxylate (4ah): Colourless oil; ^1H NMR (400 MHz, CDCl_3) δ 8.03 (s, 1H), 7.97 (d, J = 7.9 Hz, 1H), 7.54 (d, J = 8.6 Hz, 1H), 7.44 (d, J = 10.0 Hz, 5H), 3.89 (s, 3H), 3.12 (s, 2H), 2.04 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 171.3, 166.9, 156.4, 139.5, 138.5, 134.4, 132.9, 130.7, 130.2, 129.5, 129.0, 128.8, 128.4, 127.8, 52.1, 41.4, 16.9; **EI-MS** (m/z) 308 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{18}\text{H}_{16}\text{N}_2\text{O}_3$, 308.1161; found, 308.1161.

1-(3',5'-Dimethyl-[1,1'-biphenyl]-2-yl)-3-methyl-1H-pyrazol-5(4H)-one (4ai): White solid; mp = 155-157 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.45 – 7.37 (m, 4H), 7.01 – 6.90 (m, 3H), 3.11 (s, 2H), 2.30 (s, 6H), 2.05 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 171.5, 155.6, 140.2, 139.1, 137.5, 134.3, 130.9, 129.0, 128.9, 128.1, 127.9, 126.2, 41.3, 21.3, 16.9; **EI-MS** (m/z) 278 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}$, 278.1419; found, 278.1419.

1-(3'-Chloro-[1,1'-biphenyl]-2-yl)-3-methyl-1H-pyrazol-5(4H)-one (4aj): Colourless oil; ^1H NMR (400 MHz, CDCl_3) δ 7.47 – 7.40 (m, 4H), 7.35 – 7.31 (m, 1H), 7.29 – 7.26 (m, 2H), 7.25 – 7.20 (m, 1H), 3.15 (s, 2H), 2.06 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 171.4, 156.3, 141.0, 138.3, 134.3, 133.9, 130.6, 129.5, 129.0, 128.8, 128.5, 127.8, 127.3, 126.6, 41.4, 16.9; **EI-MS** (m/z) 284 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{16}\text{H}_{13}\text{ClN}_2\text{O}$, 284.0716; found, 284.0718.

1-(3'-Fluoro-[1,1'-biphenyl]-2-yl)-3-methyl-1H-pyrazol-5(4H)-one (4ak): White solid; mp = 157-159 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.43 (s, 5H), 7.17 – 6.94 (m, 3H), 3.14 (s, 2H), 2.04 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 171.4, 163.8, 161.3, 156.3, 141.5, 141.4, 138.5, 138.4, 134.3, 130.7, 129.8, 129.7, 129.0, 128.8, 127.7, 124.2(2), 115.4, 115.2, 114.2, 114.0, 41.4, 16.9; **EI-MS** (m/z) 268 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{16}\text{H}_{13}\text{FN}_2\text{O}$, 268.1012; found, 268.1015.

1-(4'-Bromo-3'-fluoro-[1,1'-biphenyl]-2-yl)-3-methyl-1H-pyrazol-5(4H)-one (4al): Colourless oil; ^1H NMR (400 MHz, CDCl_3) δ 7.52 (dd, J = 8.2, 7.2 Hz, 1H), 7.48 – 7.37 (m, 4H), 7.12 (dd, J =

9.6, 2.0 Hz, 1H), 7.01 (dd, J = 8.2, 2.0 Hz, 1H), 3.19 (s, 2H), 2.09 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 170.8, 159.3, 157.3, 156.0, 140.4, 140.3, 137.0, 133.8, 132.8, 130.1, 128.7, 128.6, 127.3, 125.0, 124.9, 116.2, 116.0, 107.6, 107.4, 41.0, 16.5; **EI-MS** (m/z) 346 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{16}\text{H}_{12}\text{BrFN}_2\text{O}$, 346.0117; found, 346.0124.

3-Methyl-1-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrazol-5(4H)-one (4ba): Colourless oil; ^1H NMR (400 MHz, CDCl_3) δ 7.38 – 7.31 (m, 4H), 7.29 (d, J = 7.9 Hz, 2H), 7.25 – 7.21 (m, 2H), 3.10 (s, 2H), 2.40 (s, 3H), 2.02 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 171.2, 155.3, 139.4, 138.9, 138.6, 131.4, 131.0, 128.5, 128.0, 127.7, 127.3, 126.7, 40.8, 20.8, 16.5; **EI-MS** (m/z) 264 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{17}\text{H}_{16}\text{N}_2\text{O}$, 264.1263; found, 264.1255.

1-(5-Chloro-[1,1'-biphenyl]-2-yl)-3-methyl-1H-pyrazol-5(4H)-one (4ca): White solid; mp = 194-196 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.44 (d, J = 2.3 Hz, 1H), 7.40 (dd, J = 8.4, 2.3 Hz, 1H), 7.37 – 7.29 (m, 6H), 3.11 (s, 2H), 2.03 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 170.9, 155.8, 141.0, 137.6, 134.0, 132.5, 130.4, 128.6, 127.9, 127.8(2), 127.3, 40.8, 16.5; **EI-MS** (m/z) 284 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{16}\text{H}_{13}\text{ClN}_2\text{O}$, 284.0716; found, 284.0710.

3-Methyl-1-(5-nitro-[1,1'-biphenyl]-2-yl)-1H-pyrazol-5(4H)-one (4da): White solid; mp = 180-182 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.31 (d, J = 2.6 Hz, 1H), 8.26 (dd, J = 8.7, 2.6 Hz, 1H), 7.65 (d, J = 8.7 Hz, 1H), 7.42 – 7.31 (m, 5H), 3.18 (s, 2H), 2.07 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 170.1, 156.6, 146.4, 139.4, 137.3, 128.2, 127.7, 127.5, 127.0, 125.8, 122.6, 40.9, 16.6; **EI-MS** (m/z) 295 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{16}\text{H}_{13}\text{N}_3\text{O}_3$, 295.0957; found, 295.0955.

3-Methyl-1-(4-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrazol-5(4H)-one (4ea): White solid; mp = 152-154 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.36 – 7.30 (m, 5H), 7.30 – 7.27 (m, 1H), 7.24 (d, J = 11.4 Hz, 2H), 3.12 (s, 2H), 2.40 (s, 3H), 2.04 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 171.5, 155.8, 139.3, 138.5, 137.2, 134.1, 130.7, 129.9, 128.5, 128.3, 128.2, 127.0, 41.4, 21.0, 17.0; **EI-MS** (m/z) 264 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{17}\text{H}_{16}\text{N}_2\text{O}$, 264.1263; found, 264.1255.

1-(4-Fluoro-[1,1'-biphenyl]-2-yl)-3-methyl-1H-pyrazol-5(4H)-one (4fa): Off-white solid; mp = 167-169 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.42 – 7.27 (m, 6H), 7.20 – 7.11 (m, 2H), 3.12 (d, J = 0.9 Hz, 2H), 2.05 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 171.0, 163.2, 160.7, 156.3, 138.6, 135.9(2), 135.5, 135.4, 132.2, 132.1, 128.4, 128.3, 127.3, 116.0, 115.8, 114.8, 114.6, 41.3, 17.0; **EI-MS** (m/z) 268 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{16}\text{H}_{13}\text{FN}_2\text{O}$, 268.1012; found, 268.1006.

1-(4-Chloro-5-methyl-[1,1'-biphenyl]-2-yl)-3-methyl-1H-pyrazol-5(4H)-one (4ga): White solid; mp = 162-164 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.42 (s, 1H), 7.36 – 7.28 (m, 6H), 3.10 (s, 2H), 2.42 (s, 3H), 2.04 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 171.4, 156.2, 138.4, 137.0, 133.6, 132.9(2), 128.3, 128.2, 127.5, 41.3, 19.9, 17.0; **EI-MS** (m/z) 298 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{17}\text{H}_{15}\text{ClN}_2\text{O}$, 298.0873; found, 298.0872.

3-Methyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1a):⁵ White solid; mp = 118-120 °C; **IR** (ν_{max}): 2922, 2851, 1656, 1597, 1492, 1442, 1409, 1313, 993, 744 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 9.13 (dd, J = 8.4, 1.2 Hz, 1H), 7.85 (ddd, J = 13.8, 7.9, 1.5 Hz, 2H), 7.43 – 7.36 (m, 2H), 7.33 – 7.28 (m, 1H), 7.26 – 7.21 (m, 2H), 5.62 (s, 1H), 2.68 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 161.6, 143.7, 134.8, 133.3, 129.0, 128.2, 124.7, 124.4, 123.4, 121.7, 121.6, 118.5, 114.9, 99.3, 16.2; **EI-MS** (m/z) 248 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{16}\text{H}_{12}\text{N}_2\text{O}$, 248.0950; found, 248.0949.

3,6-Dimethyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1b): White solid; mp = 160-162 °C; **IR** (ν_{max}): 2921, 2853, 1654, 1600, 1578, 1502, 1452, 1419, 1316, 989, 763 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 9.10 (d, J = 8.4 Hz, 1H), 7.72 (dd, J = 27.2, 8.0 Hz, 2H), 7.40 – 7.29 (m, 1H), 7.25 – 7.13 (m, 2H), 7.00 (d, J = 7.4 Hz, 1H), 5.58 (s, 1H), 2.65 (s, 3H), 2.35 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 162.0, 144.0, 139.0, 134.8, 133.6, 128.9, 126.0, 124.8, 123.7, 121.8, 119.2, 119.1, 115.8, 115.3, 99.6, 21.8, 16.7; **EI-MS** (m/z) 262 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{17}\text{H}_{14}\text{N}_2\text{O}$, 262.1106; found, 262.1102.

6-(Tert-butyl)-3-methyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1c): Colourless oil; **IR** (ν_{max}): 2953, 2863, 1660, 1617, 1600, 1492, 1409, 1319, 998, 769 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 9.15 (dd, J = 8.4, 1.2 Hz, 1H), 7.84 – 7.79 (m, 2H), 7.45 (d, J = 1.8 Hz, 1H), 7.36 (ddd, J = 8.6, 7.3, 1.5 Hz, 1H), 7.29 (dd, J = 8.4, 1.8 Hz, 1H), 7.22 (ddd, J = 8.5, 7.4, 1.3 Hz, 1H), 5.63 (d, J = 1.0 Hz, 1H), 2.72 (s, 3H), 1.36 (s, 9H); ^{13}C NMR (101 MHz, CDCl_3) δ 162.1, 152.4, 143.8, 135.1, 133.6, 129.1, 124.8, 123.6, 122.4, 121.9, 119.4, 119.1, 115.4, 112.6, 99.7, 35.1, 31.1, 16.7; **EI-MS** (m/z) 304 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}$, 304.1576; found, 304.1570.

7-Methoxy-3-methyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1d): Colourless oil; **IR** (ν_{max}): 2920, 2850, 1639, 1599, 1579, 1504, 1412, 1298, 1225, 764 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 9.15 (d, J = 8.6 Hz, 1H), 7.77 (d, J = 7.4 Hz, 1H), 7.42 – 7.31 (m, 3H), 7.22 (t, J = 7.7 Hz, 1H), 6.87 – 6.79 (m, 1H), 5.56 (s, 1H), 3.87 (s, 3H), 2.63 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 161.7, 156.4,

143.4, 135.0, 129.2, 127.2, 124.2, 123.2, 121.7, 118.4, 116.3, 114.9, 113.6, 108.4, 98.1, 55.2, 15.8;
EI-MS (m/z) 278 (M^+); **HRMS** (EI): m/z [M^+] calcd for $C_{17}H_{14}N_2O_2$, 278.1055; found, 278.1056.

Methyl 3-methyl-1-oxo-1H-benzo[c]pyrazolo[1,2-a]cinnoline-7-carboxylate (1e): Colourless oil; **IR** ($\nu_{\max}$): 2922, 2851, 1715, 1665, 1607, 1495, 1439, 1397, 1322, 1263, 986, 763 cm^{-1} ; **^1H NMR** (400 MHz, CDCl_3) δ 9.09 (d, J = 8.4 Hz, 1H), 8.51 (d, J = 1.9 Hz, 1H), 7.97 – 7.88 (m, 2H), 7.46 (d, J = 8.8 Hz, 1H), 7.43 – 7.38 (m, 1H), 7.27 (d, J = 3.2 Hz, 1H), 5.69 (s, 1H), 3.97 (s, 3H), 2.71 (s, 3H); **^{13}C NMR** (126 MHz, CDCl_3) δ 165.9, 161.7, 144.4, 136.9, 135.0, 130.0(2), 126.3, 125.3, 125.2, 122.4, 121.8, 118.2, 115.5, 114.8, 101.4, 52.4, 16.9; **EI-MS** (m/z) 306 (M^+); **HRMS** (EI): m/z [M^+] calcd for $C_{18}H_{14}N_2O_3$, 306.1004; found, 306.0999.

7-Chloro-3-methyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1f): White solid; mp = 197-199 $^{\circ}\text{C}$; **IR** ($\nu_{\max}$): 2923, 2852, 1647, 1597, 1578, 1492, 1449, 1406, 1308, 989, 799, 763 cm^{-1} ; **^1H NMR** (400 MHz, CDCl_3) δ 9.09 (d, J = 8.3 Hz, 1H), 7.75 – 7.66 (m, 2H), 7.43 – 7.35 (m, 1H), 7.31 (d, J = 8.9 Hz, 1H), 7.25 – 7.18 (m, 2H), 5.62 (s, 1H), 2.64 (s, 3H); **^{13}C NMR** (101 MHz, CDCl_3) δ 161.9, 144.3, 135.3, 132.3, 130.7, 130.2, 128.4, 125.0, 123.8, 122.3, 117.9, 116.5, 115.4, 100.2, 16.6; **EI-MS** (m/z) 282 (M^+); **HRMS** (EI): m/z [M^+] calcd for $C_{16}H_{11}\text{ClN}_2\text{O}$, 282.0560; found, 282.0558.

7-Fluoro-3-methyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1g): Off-white solid; mp = 190-192 $^{\circ}\text{C}$; **IR** ($\nu_{\max}$): 2923, 2853, 1659, 1599, 1581, 1507, 1436, 1403, 1319, 1212, 989, 796, 760 cm^{-1} ; **^1H NMR** (400 MHz, CDCl_3) δ 9.10 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.47 (dd, J = 9.4, 2.9 Hz, 1H), 7.42 – 7.30 (m, 2H), 7.22 (t, J = 7.3 Hz, 1H), 6.98 (ddd, J = 9.0, 7.5, 2.9 Hz, 1H), 5.60 (s, 1H), 2.63 (s, 3H); **^{13}C NMR** (126 MHz, CDCl_3) δ 161.6, 160.4, 158.4, 143.8, 134.9, 129.8, 129.7, 129.6, 124.4, 124.0(2), 121.9, 117.7(2), 116.6, 116.5, 115.0, 114.9, 114.8, 110.2, 110.0, 99.1, 15.9; **EI-MS** (m/z) 266 (M^+); **HRMS** (EI): m/z [M^+] calcd for $C_{16}H_{11}\text{FN}_2\text{O}$, 266.0855; found, 266.0857.

6-Chloro-3-methyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1h): Off-white solid; mp = 139-141 $^{\circ}\text{C}$; **IR** ($\nu_{\max}$): 2923, 2851, 1658, 1633, 1599, 1487, 1417, 1296, 1103, 998, 758 cm^{-1} ; **^1H NMR** (400 MHz, CDCl_3) δ 9.07 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 13.1 Hz, 2H), 7.41 – 7.34 (m, 2H), 7.24 – 7.13 (m, 2H), 5.63 (s, 1H), 2.67 (s, 3H); **^{13}C NMR** (101 MHz, CDCl_3) δ 161.8, 144.3, 135.0, 134.5, 134.2, 129.8, 125.1, 125.0, 122.1, 120.6, 118.2, 115.4(2), 100.8, 16.6; **EI-MS** (m/z) 282 (M^+); **HRMS** (EI): m/z [M^+] calcd for $C_{16}H_{11}\text{ClN}_2\text{O}$, 282.0560; found, 282.0560.

3,7-Dimethyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1i): White solid; mp = 161-163 °C; **IR** (ν_{max}): 2919, 2855, 1645, 1598, 1581, 1507, 1449, 1409, 1311, 990, 767 cm^{-1} ; **^1H NMR** (400 MHz, CDCl_3) δ 9.12 (d, J = 7.3 Hz, 1H), 7.76 (d, J = 6.4 Hz, 1H), 7.57 (s, 1H), 7.38 – 7.30 (m, 1H), 7.24 – 7.15 (m, 2H), 7.03 (dd, J = 8.5, 1.2 Hz, 1H), 5.55 (s, 1H), 2.60 (s, 3H), 2.35 (s, 3H); **^{13}C NMR** (126 MHz, CDCl_3) δ 161.5, 143.4, 134.7, 134.3, 131.0, 128.8(2), 124.2, 123.7, 121.5, 121.2, 118.5, 114.9, 114.7, 98.6, 20.5, 16.0; **EI-MS** (m/z) 262 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{17}\text{H}_{14}\text{N}_2\text{O}$, 262.1106; found, 262.1101.

3,10-Dimethyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1j): White solid; mp = 184-186 °C; **IR** (ν_{max}): 2923, 2857, 1684, 1601, 1495, 1421, 1318, 1213, 1140, 800 cm^{-1} ; **^1H NMR** (400 MHz, MeOD) δ 8.71 (s, 1H), 7.77 (d, J = 6.4 Hz, 1H), 7.66 (d, J = 8.2 Hz, 1H), 7.47 (d, J = 7.3 Hz, 1H), 7.27 (ddd, J = 8.5, 7.3, 1.5 Hz, 1H), 7.18 (td, J = 7.5, 1.1 Hz, 1H), 6.98 (d, J = 9.1 Hz, 1H), 5.59 (s, 1H), 2.63 (s, 3H), 2.31 (s, 3H); **^{13}C NMR** (126 MHz, MeOD) δ 161.5, 144.5, 138.9, 133.3, 132.1, 127.8, 125.5, 124.8, 122.7, 121.6, 120.6, 115.7, 115.0, 114.6, 97.8, 19.9, 14.9; **EI-MS** (m/z) 262 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{17}\text{H}_{14}\text{N}_2\text{O}$, 262.1106; found, 262.1099.

10-Chloro-3-methyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1k): Off-white solid; mp = 195-197 °C; **IR** (ν_{max}): 2923, 2852, 1659, 1592, 1577, 1451, 1415, 1337, 987, 775 cm^{-1} ; **^1H NMR** (400 MHz, CDCl_3) δ 9.09 (d, J = 9.0 Hz, 1H), 7.80 – 7.73 (m, 2H), 7.42 (dd, J = 8.3, 1.2 Hz, 1H), 7.35 – 7.28 (m, 2H), 7.25 (dd, J = 7.7, 1.2 Hz, 1H), 5.61 (s, 1H), 2.68 (s, 3H); **^{13}C NMR** (126 MHz, CDCl_3) δ 161.8, 144.4, 134.0, 133.6, 130.2, 129.5, 129.1, 125.2, 124.0, 122.0, 120.8(2), 116.8, 115.4, 99.8, 16.7; **EI-MS** (m/z) 282 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{16}\text{H}_{11}\text{ClN}_2\text{O}$, 282.0560; found, 282.0558.

3,11-Dimethyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1l): Pale yellow solid; mp = 200-202 °C; **IR** (ν_{max}): 2923, 2853, 1645, 1602, 1578, 1501, 1451, 1419, 1337, 988, 762 cm^{-1} ; **^1H NMR** (400 MHz, CDCl_3) δ 9.02 (d, J = 8.6 Hz, 1H), 7.87 (dd, J = 7.8, 1.6 Hz, 1H), 7.62 (s, 1H), 7.42 (dd, J = 8.3, 1.2 Hz, 1H), 7.32 – 7.27 (m, 1H), 7.26 – 7.17 (m, 2H), 5.61 (s, 1H), 2.68 (s, 3H), 2.40 (s, 3H); **^{13}C NMR** (126 MHz, CDCl_3) δ 161.9, 143.8, 134.3, 133.9, 133.1, 130.2, 128.6, 125.0, 123.9, 122.5, 122.1, 118.8, 115.4, 115.3, 99.9, 21.2, 16.7; **EI-MS** (m/z) 262 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{17}\text{H}_{14}\text{N}_2\text{O}$, 262.1106; found, 262.1098.

11-Fluoro-3-methyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1m): Pale yellow solid; mp =

178-180 °C; **IR** ($\nu_{\max}$): 2923, 2851, 1656, 1605, 1496, 1424, 1276, 1186, 917, 753 cm^{-1} ; **^1H NMR** (400 MHz, CDCl_3) δ 8.93 (d, J = 11.4 Hz, 1H), 7.74 (d, J = 7.8 Hz, 2H), 7.38 (d, J = 8.4 Hz, 1H), 7.26 (d, J = 6.4 Hz, 1H), 7.21 (t, J = 8.1 Hz, 1H), 6.93 – 6.86 (m, 1H), 5.58 (s, 1H), 2.66 (s, 3H); **^{13}C NMR** (101 MHz, CDCl_3) δ 164.1, 161.9, 161.6, 144.7, 136.1, 136.0, 133.1, 128.6, 125.3, 123.8, 123.7, 123.6, 121.4, 115.6, 115.4, 115.2(2), 112.1, 111.8, 103.2, 102.9, 99.4, 16.6; **EI-MS** (m/z) 266 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{16}\text{H}_{11}\text{FN}_2\text{O}$, 266.0855; found, 266.0848.

11-Chloro-3,10-dimethyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1r): White solid; mp = 182-184 °C; **IR** ($\nu_{\max}$): 2920, 2849, 1655, 1603, 1575, 1492, 1448, 1411, 1320, 994, 753 cm^{-1} ; **^1H NMR** (400 MHz, CDCl_3) δ 9.12 (s, 1H), 7.75 (d, J = 9.0 Hz, 1H), 7.58 (s, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.32 – 7.27 (m, 1H), 7.20 (t, J = 7.5 Hz, 1H), 5.57 (s, 1H), 2.66 (s, 3H), 2.38 (s, 3H); **^{13}C NMR** (126 MHz, CDCl_3) δ 161.6, 144.3, 135.3, 133.6, 133.5, 132.3, 128.8, 125.1, 123.9, 123.7, 121.2, 117.5, 115.7, 115.3, 99.5, 19.9, 16.6; **EI-MS** (m/z) 296 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{17}\text{H}_{13}\text{ClN}_2\text{O}$, 296.0716; found, 296.0716.

10-Fluoro-3-methyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1o): Off-white solid; mp = 199-201 °C; **IR** ($\nu_{\max}$): 2923, 2851, 1642, 1603, 1500, 1453, 1433, 1273, 1191, 992, 892, 817, 777 cm^{-1} ; **^1H NMR** (400 MHz, CDCl_3) δ 9.13 (dd, J = 9.3, 5.3 Hz, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.48 – 7.38 (m, 2H), 7.36 – 7.29 (m, 1H), 7.26 – 7.19 (m, 1H), 7.05 (ddd, J = 9.3, 7.8, 2.8 Hz, 1H), 5.62 (d, J = 1.1 Hz, 1H), 2.67 (s, 3H); **^{13}C NMR** (126 MHz, CDCl_3) δ 161.3, 160.2, 158.3, 143.6, 133.6, 131.0, 129.0, 124.7, 123.6, 120.7, 120.6(2), 117.0, 116.9, 115.7, 115.5, 114.9, 108.3, 108.1, 99.5, 16.2; **EI-MS** (m/z) 266 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{16}\text{H}_{11}\text{FN}_2\text{O}$, 266.0855; found, 266.0862.

10-Bromo-3-methyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1p): White solid; mp = 192-194 °C; **IR** ($\nu_{\max}$): 2924, 2852, 1644, 1588, 1485, 1418, 1312, 990, 817, 753 cm^{-1} ; **^1H NMR** (400 MHz, CDCl_3) δ 8.99 (d, J = 9.0 Hz, 1H), 7.83 (d, J = 2.2 Hz, 1H), 7.71 (d, J = 6.8 Hz, 1H), 7.42 – 7.33 (m, 2H), 7.32 – 7.27 (m, 1H), 7.24 – 7.16 (m, 1H), 5.58 (s, 1H), 2.65 (s, 3H); **^{13}C NMR** (126 MHz, CDCl_3) δ 161.7, 144.4, 134.0, 133.9, 131.9, 129.4, 125.2, 124.9, 124.0, 121.0, 120.6, 117.8, 117.0, 115.3, 99.7, 16.7; **EI-MS** (m/z) 326 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{16}\text{H}_{11}\text{BrN}_2\text{O}$, 326.0055; found, 326.0049.

11-Bromo-3-methyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1n): White solid; mp =

166-168 °C; **IR** ($\nu_{\max}$): 2923, 2851, 1664, 1604, 1588, 1485, 1416, 1313, 1258, 993, 751 cm^{-1} ; **^1H NMR** (400 MHz, CDCl_3) δ 9.31 (s, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.36 – 7.28 (m, 2H), 7.22 (t, J = 7.4 Hz, 1H), 5.60 (s, 1H), 2.67 (s, 3H); **^{13}C NMR** (126 MHz, CDCl_3) δ 161.4, 144.3, 135.3, 133.2, 128.6, 127.5, 124.8, 123.3, 122.9, 122.8, 120.8, 117.7, 117.5, 115.0, 99.1, 16.2; **EI-MS** (m/z) 326 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{16}\text{H}_{11}\text{BrN}_2\text{O}$, 326.0055; found, 326.0059.

3,10,11-Trimethyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1q): Colourless oil; **IR** ($\nu_{\max}$): 2921, 2852, 1652, 1603, 1495, 1449, 1415, 1352, 1323, 895, 752 cm^{-1} ; **^1H NMR** (400 MHz, CDCl_3) δ 8.91 (s, 1H), 7.83 (d, J = 7.5 Hz, 1H), 7.56 (s, 1H), 7.40 (d, J = 8.1 Hz, 1H), 7.27 (t, J = 3.4 Hz, 1H), 7.20 (t, J = 7.5 Hz, 1H), 5.60 (s, 1H), 2.66 (s, 3H), 2.31 (d, 6H); **^{13}C NMR** (126 MHz, CDCl_3) δ 161.8, 143.6, 138.6, 133.5, 133.2, 128.0, 124.9, 123.5, 122.9, 122.2, 116.4, 116.1, 115.3, 99.7, 20.1, 19.6, 16.6; **EI-MS** (m/z) 276 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{18}\text{H}_{16}\text{N}_2\text{O}$, 276.1263; found, 276.1276.

1H-Benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1s): Pale yellow solid; mp = 126-128 °C; **IR** ($\nu_{\max}$): 2924, 2853, 1646, 1596, 1530, 1492, 1450, 1344, 1275, 744 cm^{-1} ; **^1H NMR** (400 MHz, CDCl_3) δ 9.16 (d, J = 8.4 Hz, 1H), 7.94 (d, J = 3.8 Hz, 1H), 7.75 (dd, J = 7.8, 5.6 Hz, 2H), 7.39 – 7.31 (m, 1H), 7.29 – 7.24 (m, 1H), 7.22 – 7.16 (m, 1H), 7.12 (t, J = 7.7 Hz, 2H), 5.80 (d, J = 3.8 Hz, 1H); **^{13}C NMR** (126 MHz, CDCl_3) δ 161.8, 133.8, 131.9, 129.6, 129.4, 126.6, 125.1, 124.8, 123.4, 121.9, 118.7, 118.0, 116.0, 111.8, 97.2; **EI-MS** (m/z) 234 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{15}\text{H}_{10}\text{N}_2\text{O}$, 234.0793; found, 234.0802.

3-Ethyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1t): White solid; mp = 104-106 °C; **IR** ($\nu_{\max}$): 2922, 2852, 1649, 1600, 1489, 1445, 1308, 747 cm^{-1} ; **^1H NMR** (400 MHz, CDCl_3) δ 9.11 (d, J = 8.4 Hz, 1H), 7.85 – 7.77 (m, 2H), 7.36 (dd, J = 14.8, 7.6 Hz, 2H), 7.31 – 7.26 (m, 1H), 7.22 (t, J = 7.5 Hz, 2H), 5.67 (s, 1H), 3.00 (q, J = 7.5 Hz, 2H), 1.39 – 1.34 (m, 3H); **^{13}C NMR** (126 MHz, CDCl_3) δ 162.4, 151.0, 135.5, 134.0, 129.5, 128.6, 125.1, 124.8, 124.0, 122.4, 122.2, 119.2, 115.7, 115.3, 98.2, 23.2, 12.5.; **EI-MS** (m/z) 262 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{17}\text{H}_{14}\text{N}_2\text{O}$, 276.1106; found, 262.1099.

3-Isopropyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1u): Colourless oil; **IR** ($\nu_{\max}$): 2974, 1658, 1599, 1554, 1502, 1487, 1442, 1300, 750 cm^{-1} ; **^1H NMR** (400 MHz, CDCl_3) δ 9.08 (d, J = 7.9

Hz, 1H), 7.84 (d, $J = 7.8$ Hz, 2H), 7.39 (dd, $J = 17.1, 8.4$ Hz, 2H), 7.33 (d, $J = 7.1$ Hz, 1H), 7.28 – 7.21 (m, 2H), 5.72 (s, 1H), 3.50 (p, $J = 6.8$ Hz, 1H), 1.40 (d, $J = 6.7$ Hz, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 162.8, 157.1, 135.8, 134.3, 129.5, 128.7, 125.4, 124.8, 124.3, 123.2, 122.3, 119.7, 116.0, 115.2, 97.7, 27.7, 22.5; **EI-MS** (m/z) 276 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{18}\text{H}_{16}\text{N}_2\text{O}$, 276.1263; found, 276.1268.

2,3-Dimethyl-1H-benzo[c]pyrazolo[1,2-a]cinnolin-1-one (1v): White solid; mp = 146-148 °C; **IR** (ν_{max}): 2921, 2852, 1645, 1610, 1491, 1442, 1384, 1320, 753 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 9.09 (d, $J = 7.3$ Hz, 1H), 7.87 – 7.78 (m, 2H), 7.37 (d, $J = 8.8$ Hz, 2H), 7.28 (d, $J = 6.9$ Hz, 1H), 7.25 – 7.18 (m, 2H), 2.62 (s, 3H), 2.00 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 162.0, 140.6, 135.3, 134.5, 129.4, 128.6, 124.7, 124.5, 124.0, 122.2(2), 119.6, 115.4, 115.1, 107.2, 14.46, 6.93; **EI-MS** (m/z) 262 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{17}\text{H}_{14}\text{N}_2\text{O}$, 262.1106; found, 262.1109.

Methyl 3-methyl-1-oxo-1H-benzo[c]pyrazolo[1,2-a]cinnoline-2-carboxylate (1w): White solid; mp = 165-167 °C; **IR** (ν_{max}): 2923, 2853, 1684, 1546, 1507, 1438, 1273, 1204, 751 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 9.15 (d, $J = 8.4$ Hz, 1H), 7.92 – 7.84 (m, 2H), 7.49 (dt, $J = 7.8, 4.1$ Hz, 1H), 7.45 – 7.36 (m, 3H), 7.27 (d, $J = 2.4$ Hz, 1H), 3.94 (s, 3H), 3.01 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 164.4, 159.7, 150.0, 135.5, 131.8, 130.1, 128.5, 127.2, 125.2, 124.3(2), 122.4, 118.8, 118.1, 115.1, 100.7, 51.6, 15.7; **EI-MS** (m/z) 306 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{18}\text{H}_{14}\text{N}_2\text{O}_3$, 306.1004; found, 306.1011.

1-([1,1'-Biphenyl]-2-yl)-3,4,4-trimethyl-1H-pyrazol-5(4H)-one (7): Colourless oil; ^1H NMR (400 MHz, CDCl_3) δ 7.43 (s, 4H), 7.36 – 7.25 (m, 5H), 1.95 (s, 3H), 1.07 (s, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 176.9, 164.5, 140.2, 139.3, 134.5, 130.7, 128.8, 128.7, 128.3, 128.0, 127.8, 127.2, 48.5, 20.5, 13.2; **EI-MS** (m/z) 278 (M^+); **HRMS** (EI): m/z [M^+] calcd for $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}$, 278.1419; found, 278.1421.


Palladacycle (I): ^1H NMR (400 MHz, CD_3CN) δ 7.71 (d, $J = 7.9$ Hz, 1H), 7.17 (t, $J = 7.4$ Hz, 1H), 7.12 (d, $J = 7.8$ Hz, 1H), 6.86 (t, $J = 7.5$ Hz, 1H), 5.52 (s, 1H), 2.08 (s, 3H).

8. References


1. K. J. Duffy, C. L. Erickson-Miller, D. F. Eppley, J. Jenkins, J. I. Luengo, N. Liu, A. T. Price, A. N. Shaw, S. Vison-Neau and K. Wiggall, WO 089457 A2, 2001.
2. D. Castagnolo, A. de Logu, M. Radi, B. Bechi, F. Manetti, M. Magnani, S. Supino, R. Meleddu, L. Chisu and M. Botta, *Bioorg. Med. Chem.* 2008, **16**, 8587.
3. K. Watanabe, Y. Morinaka, K. Iseki, T. Watanabe, S. Yuki and H. Nishi, *Redox Rep.* 2003, **8**, 151.
4. W. F. Beech and M. Mendoza, GB 560892, 1944.
5. (a) E. Andre, A. Georges and A. Serge, *Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques* 1967, **264**, 1855; (b) E. Andre and I. Georges, *Bulletin de la Societe Chimique de France* 1964, **11**, 2897; (c) E. Andre and P. Rene, *Bulletin de la Societe Chimique de France* 1962, 292.

9. Copies of NMR Data for All New Compounds.



^1H and ^{13}C NMR spectra of compound **4aa**.





^1H and ^{13}C NMR spectra of compound **4ab**.





^1H and ^{13}C NMR spectra of compound **4ac**.





^1H and ^{13}C NMR spectra of compound **4ad**.





^1H and ^{13}C NMR spectra of compound **4af**.




^1H and ^{13}C NMR spectra of compound **4ag**.





^1H and ^{13}C NMR spectra of compound **4ah**.





^1H and ^{13}C NMR spectra of compound **4ai**.





^1H and ^{13}C NMR spectra of compound **4aj**.





^1H and ^{13}C NMR spectra of compound **4ak**.





^1H and ^{13}C NMR spectra of compound **4al**.





^1H and ^{13}C NMR spectra of compound **4ba**.





^1H and ^{13}C NMR spectra of compound **4ca**.





^1H and ^{13}C NMR spectra of compound **4da**.





^1H and ^{13}C NMR spectra of compound **4ea**.





^1H and ^{13}C NMR spectra of compound **4fa**.




^1H and ^{13}C NMR spectra of compound **4ga**.





^1H and ^{13}C NMR spectra of compound **1a**.




^1H and ^{13}C NMR spectra of compound **1b**.





^1H and ^{13}C NMR spectra of compound **1c**.




^1H and ^{13}C NMR spectra of compound **1d**.





^1H and ^{13}C NMR spectra of compound **1e**.





^1H and ^{13}C NMR spectra of compound **1f**.





^1H and ^{13}C NMR spectra of compound **1g**.





^1H and ^{13}C NMR spectra of compound **1h**.





^1H and ^{13}C NMR spectra of compound **1i**.




^1H and ^{13}C NMR spectra of compound **1j**.





^1H and ^{13}C NMR spectra of compound **1k**.





^1H and ^{13}C NMR spectra of compound **11**.





^1H and ^{13}C NMR spectra of compound **1m**.





^1H and ^{13}C NMR spectra of compound **10**.




^1H and ^{13}C NMR spectra of compound **1p**.





^1H and ^{13}C NMR spectra of compound **1n**.





^1H and ^{13}C NMR spectra of compound **1q**.




^1H and ^{13}C NMR spectra of compound **1s**.




^1H and ^{13}C NMR spectra of compound **1t**.




^1H and ^{13}C NMR spectra of compound **1u**.





^1H and ^{13}C NMR spectra of compound **1v**.




^1H and ^{13}C NMR spectra of compound **1w**.



^1H and ^{13}C NMR spectra of compound 7.



¹H NMR spectra of compound **I**.



10. X-ray Data of Compound **1n**.




Table 4 Crystal data and structure refinement details for compound **1n**.

Identification code	2013251
Chemical formula	C ₁₆ H ₁₁ BrN ₂ O
Formula weight	326.01

Temperature	296(2) K	
Wavelength	0.71073 Å	
Crystal size	0.020 x 0.080 x 0.200 mm	
Crystal system	orthorhombic	
Space group	P c a 21	
Unit cell dimensions	a = 7.4355(4) Å	$\alpha = 90^\circ$
	b = 20.5015(12) Å	$\beta = 90^\circ$
	c = 16.7167(9) Å	$\gamma = 90^\circ$
Volume	2548.3(2) Å ³	
Z	4	
Density (calculated)	1.698 Mg/cm ³	
Absorption coefficient	3.222 mm ⁻¹	
F(000)	1300	
Theta range for data collection	0.99 to 27.51°	
Index ranges	-9<=h<=9, -26<=k<=26, -21<=l<=21	
Reflections collected	39317	
Independent reflections	5862 [R(int) = 0.1042]	
Coverage of independent reflections	100.0%	
Absorption correction	multi-scan	
Structure solution technique	direct methods	
Structure solution program	SHELXS-97 (Sheldrick, 2008)	
Refinement method	Full-matrix least-squares on F ²	
Refinement program	SHELXL-97 (Sheldrick, 2008)	
Function minimized	$\Sigma w(F_o^2 - F_c^2)^2$	
Data / restraints / parameters	5862 / 1 / 362	
Goodness-of-fit on F ²	0.907	
$\Delta/\sigma_{\max}$	0.863	
Final R indices	2893 data; I>2σ(I)	R1 = 0.0553, wR2 = 0.1352
	all data	R1 = 0.1439, wR2 = 0.1773
Weighting scheme	w=1/[σ ² (F _o ²)+(0.1000P) ² +0.0000P] where P=(F _o ² +2F _c ²)/3	
Absolute structure parameter	0.4(0)	
Largest diff. peak and hole	0.304 and -0.457 eÅ ⁻³	
R.M.S. deviation from mean	0.069 eÅ ⁻³	